Privia Health Group (NASDAQ:PRVA – Get Free Report) had its price target increased by Piper Sandler from $36.00 to $38.00 in a research note issued on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Piper Sandler‘s price target indicates a potential upside of 60.34% from the stock’s previous close.
Several other brokerages have also issued reports on PRVA. Citigroup reiterated a “buy” rating on shares of Privia Health Group in a report on Thursday, July 23rd. Canaccord Genuity Group set a $32.00 price objective on Privia Health Group in a report on Friday, August 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Privia Health Group in a research report on Tuesday, September 29th. Finally, Zacks Research upgraded Privia Health Group from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 5th. Eleven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $31.15.
Check Out Our Latest Analysis on Privia Health Group
Privia Health Group Price Performance
PRVA stock opened at $23.70 on Friday. The stock has a market capitalization of $3.03 billion, a PE ratio of 112.86 and a beta of 0.76. The company’s 50-day moving average is $20.97 and its 200-day moving average is $22.63. Privia Health Group has a 1 year low of $18.92 and a 1 year high of $28.82.
Privia Health Group (NASDAQ:PRVA – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.21 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.12. Privia Health Group had a return on equity of 3.52% and a net margin of 1.19%. The business had revenue of $656.96 million during the quarter, compared to analyst estimates of $610.72 million. During the same period in the previous year, the company posted $0.29 EPS. The firm’s revenue was up 13.2% compared to the same quarter last year. On average, analysts anticipate that Privia Health Group will post 0.27 earnings per share for the current fiscal year.
Institutional Trading of Privia Health Group
Institutional investors have recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Privia Health Group in the second quarter valued at about $550,684,000. Rubicon Founders LLC bought a new position in shares of Privia Health Group during the second quarter valued at about $153,635,863. Van Berkom & Associates Inc. boosted its holdings in Privia Health Group by 5.4% during the first quarter. Van Berkom & Associates Inc. now owns 4,053,043 shares of the company’s stock worth $83,371,000 after purchasing an additional 208,787 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Privia Health Group during the second quarter worth about $74,425,000. Finally, Dimensional Fund Advisors LP boosted its holdings in Privia Health Group by 6.3% during the first quarter. Dimensional Fund Advisors LP now owns 2,406,717 shares of the company’s stock worth $49,500,000 after purchasing an additional 142,679 shares during the last quarter. Institutional investors own 94.48% of the company’s stock.
Privia Health Group News Summary
Here are the key news stories impacting Privia Health Group this week:
- Positive Sentiment: Privia reported Q3 revenue of $656.96 million, up 13.2% year over year and above analysts’ $610.72 million estimate. Earnings per share of $0.21 also topped the $0.09 consensus estimate. Privia Health Q3 results
- Positive Sentiment: The company raised its 2026 guidance across all key financial metrics. Year-to-date adjusted EBITDA reached $114.7 million, a 21.9% increase from the same period in 2025, supporting the case for continued operating growth. Privia Health guidance and results
- Positive Sentiment: A valuation analysis published after the earnings report argues PRVA could be about 24% undervalued, adding a bullish valuation view; this is an estimate, not company guidance. Valuation analysis
- Negative Sentiment: Despite the earnings beat, reported EPS was below the year-ago $0.29 figure. The company’s 1.19% net margin is also slim, while its reported P/E ratio of 114 may leave the stock sensitive to any disappointment in growth or execution.
About Privia Health Group
Privia Health Group, Inc is a physician-enablement company that partners with independent medical practices to support the delivery of coordinated, value-based care. The company provides an integrated platform designed to help physicians manage clinical, administrative and financial functions while maintaining ownership and control of their practices.
Its services include practice management, electronic health record and technology support, revenue-cycle management, payer contracting, population-health analytics, care-management programs and administrative assistance.
See Also
- Five stocks we like better than Privia Health Group
- 3 Dividend ETFs Offer Different Ways to Navigate the Post-Election Sell-Off
- Riot’s $28B Lease Shows Why Location and Contracts Matter in AI
- These 3 Underperforming Stocks Are Seeing Notable CEO Insider Trades
- GE Aerospace Has a $170 Billion Backlog, But Is the Stock Worth the Premium?
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
